Sign In
Buy PCRX
$22.25
-0.710 (-3.09%)
At Close: Jun 02, 2026
Northland Capital Markets Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target to $50
12:00am, Tuesday, 07'th Apr 2020Mason Street Advisors LLC Has $658,000 Stock Holdings in Pacira Biosciences Inc (NASDAQ:PCRX)
12:08pm, Monday, 06'th Apr 2020
Mason Street Advisors LLC raised its position in Pacira Biosciences Inc (NASDAQ:PCRX) by 2.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and
How This Top Fund Manager Seeks Stocks That Benefit From The Coronavirus Stock Market
12:00pm, Monday, 06'th Apr 2020
Amid the coronavirus stock market crash, Delaware Funds' Alex Ely seeks stocks that benefit from the crisis.
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Seattle Genetics (SGEN)
02:40am, Monday, 06'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pfizer (PFE) and Seattle Genetics (SGEN) with bullish
How This Top Fund Manager Seeks Stocks That Benefit From The Coronavirus Stock Market
12:00am, Monday, 06'th Apr 2020Goldman Sachs Group Inc. Acquires 27,913 Shares of Pacira Biosciences Inc (NASDAQ:PCRX)
10:12am, Friday, 03'rd Apr 2020
Goldman Sachs Group Inc. raised its position in shares of Pacira Biosciences Inc (NASDAQ:PCRX) by 9.3% in the fourth quarter, according to the company in its most recent filing with the Securities & E
RBC Capital Maintains a Hold Rating on Endo International (ENDP)
05:33pm, Thursday, 02'nd Apr 2020
RBC Capital analyst Randall Stanicky maintained a Hold rating on Endo International (ENDP) today and set a price target of $6.00. The company's shares
RBC Capital Maintains a Hold Rating on Endo International (ENDP)
05:33pm, Thursday, 02'nd Apr 2020
RBC Capital analyst
Randall Stanicky
maintained a
Hold
rating on Endo International (
ENDP
–
Research Report
) today and set a price target of
$6.00
. The company’s shares closed last Thursday at
Stifel Nicolaus Sticks to Its Buy Rating for Principia Biopharma (PRNB)
08:51am, Thursday, 02'nd Apr 2020
In a report issued on March 29, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Principia Biopharma (PRNB), with a price target of $76.00.
Stifel Nicolaus Sticks to Its Buy Rating for Principia Biopharma (PRNB)
08:51am, Thursday, 02'nd Apr 2020
In a report issued on March 29,
Derek Archila
from Stifel Nicolaus reiterated a
Buy
rating on Principia Biopharma (
PRNB
–
Research Report
), with a price target of
$76.00
. The company’s shares c
RBC Capital Remains a Hold on Teva Pharmaceutical Industries (TEVA)
01:43pm, Wednesday, 01'st Apr 2020
RBC Capital analyst Randall Stanicky maintained a Hold rating on Teva Pharmaceutical Industries (TEVA) today and set a price target of $11.00. The
Merck & Company (MRK) Gets a Hold Rating from RBC Capital
01:42pm, Wednesday, 01'st Apr 2020
RBC Capital analyst Randall Stanicky maintained a Hold rating on Merck & Company (MRK) today and set a price target of $89.00. The company's shares
Merck & Company (MRK) Gets a Hold Rating from RBC Capital
01:42pm, Wednesday, 01'st Apr 2020
RBC Capital analyst
Randall Stanicky
maintained a
Hold
rating on Merck & Company (
MRK
–
Research Report
) today and set a price target of
$89.00
. The company’s shares closed last Monday at $76.9
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Danaher (DHR), Amneal Pharmaceuticals (AMRX) and CytomX
Envestnet Asset Management Inc. Makes New Investment in Pacira Biosciences Inc (NASDAQ:PCRX)
10:42am, Tuesday, 31'st Mar 2020
Envestnet Asset Management Inc. purchased a new position in shares of Pacira Biosciences Inc (NASDAQ:PCRX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Co
